Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
647 clinical trials found
Clinical trials

EFC17600

A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 48-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered as monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (NCT06407934)

No longer recruiting

eFemoral

A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal Artery (NCT04584632)

This trial is looking at a new treatment called the Efemoral Vascular Scaffold System (EVSS), a tiny dissolvable scaffold coated with medication that helps keep blood flowing in narrowed or blocked leg arteries. VSS is designed to support the artery while it heals and then gradually dissolve, leaving the vessel free to move naturally. This may improve circulation, reduce symptoms like leg pain when walking, and support long-term artery health.
Currently recruiting

EFFECT

Investigating the immunomodulatory and clinical effects of fermentable fibre intervention to reduce symptoms of Long COVID (ACTRN12624000356561)

Currently recruiting

ELEVATE-HFpEF

Randomized trial of ELEVATEd cardiac pacing rate for personalized treatment of Heart Failure with preserved Ejection Fraction [ELEVATE-HFpEF] (NCT06678841)

Currently recruiting

Eli-Lily I7P-MC-DSAF

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa (NCT06046729)

No longer recruiting

ELOWEN-1

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (NCT07332481)

This trial aims to evaluate the safety and efficacy of enpatoran over 24 weeks in people with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration up to 35 weeks, Treatment Duration 24 weeks, Visit Frequency every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.

Coming soon

EMERALD-2

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who are at high risk of reccurence after curative hepatic resection or ablation (NCT03847428)

Currently recruiting

EMITT-1 GREY WOLF

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies (ACTRN12623000108617)

Currently recruiting

ENCOMPASS

A Prospective, Single-Arm, Multicenter Feasibility Trial to Evaluate the Safety and Performance of the F2 Filter and Delivery System Used for Embolic Protection During Transcatheter Aortic Valve Replacement (NCT05893082)

No longer recruiting

ENDURE-AF

Left Atrial Posterior Wall Isolation VS Left Atrial Posterior Wall isolation and Superior Vena Cava Isolation and Cavo-tricuspid isthmus Isolation and Mitral Isthmus Isolation for Recurrent Atrial Fibrillation Post Pulmonary Vein Isolation – A Randomised Control Trial (The ENDURE-AF randomised control trial) (ACTRN12624000676516)

Coming soon

ENVISION

ABT-CIP-10487 ENVISION Trial - Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients (NCT05932615)

Currently recruiting

EOHC

An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer (ACTRN12620000583943)

Currently recruiting

Epidyolex Study

Effect of cannabidiol on sleep in developmental and epileptic encephalopathies (ACTRN12623000855628p)

Currently recruiting

EPIMINDER

A prospective study to assess the safety of a sub-scalp monitoring device for the recording of brain electrical activity associated with the occurrence of epileptic seizures (ACTRN12619001587190)

Currently recruiting

EpLCART

A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation with Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma (NCT06414148)

Currently recruiting

EPO_TRAUMA

A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in machnically ventilated critically ill patients following traumatic injury. (ACTRN12619001632189)

Currently recruiting

ERASER

A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT04305249)

No longer recruiting

Estradiol in CTD

A randomised placebo controlled trial of estradiol for the treatment of women with borderline personality disorder. (ACTRN12617001317381)

Currently recruiting

EVACUATE

Ultra-Early, minimally inVAsive intraCerebral haemorrhage evacUATion versus standard trEatment (EVACUATE) (NCT04434807)

Currently recruiting

EVOLVE

A Phase 2 Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The EvolvE Study) (NCT05774184)

Currently recruiting
11 12 13 14 15